{"id":95402,"date":"2026-05-24T06:52:08","date_gmt":"2026-05-24T06:52:08","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/95402\/"},"modified":"2026-05-24T06:52:08","modified_gmt":"2026-05-24T06:52:08","slug":"ocni-mrtvice-ci-paralyza-zaludku-vedci-popsali-vedlejsi-ucinky-nejen-ozempicu-v-usa-se-hromadi-zaloby","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/95402\/","title":{"rendered":"O\u010dn\u00ed mrtvice \u010di paral\u00fdza \u017ealudku, v\u011bdci popsali vedlej\u0161\u00ed \u00fa\u010dinky nejen Ozempicu. V USA se hromad\u00ed \u017ealoby"},"content":{"rendered":"

Popularita l\u00e9k\u016f na hubnut\u00ed, jako jsou Ozempic<\/a>,\u00a0Wegovy nebo Mounjaro, d\u00e1l prudce roste. Jen ve Spojen\u00fdch st\u00e1tech je podle odhad\u016f u\u017e\u00edv\u00e1 zhruba ka\u017ed\u00fd osm\u00fd dosp\u011bl\u00fd a jejich obliba s\u00edl\u00ed i v \u010cesku. S t\u00edm ale p\u0159ib\u00fdv\u00e1 i pacient\u016f, kte\u0159\u00ed upozor\u0148uj\u00ed na v\u00e1\u017en\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky.\u00a0<\/p>\n

V USA se kv\u016fli nim za\u010d\u00ednaj\u00ed mno\u017eit \u017ealoby na farmaceutick\u00e9 firmy\u00a0Novo Nordisk<\/a>\u00a0a Eli Lilly a nov\u00e9 studie z\u00e1rove\u0148 upozor\u0148uj\u00ed na dal\u0161\u00ed zdravotn\u00ed rizika, o nich\u017e se d\u0159\u00edve tolik nemluvilo.\u00a0<\/p>\n

Do centra pozornosti se dost\u00e1vaj\u00ed p\u0159edev\u0161\u00edm l\u00e9ky ze skupiny takzvan\u00fdch agonist\u016f GLP-1. Pat\u0159\u00ed mezi n\u011b semaglutid prod\u00e1van\u00fd pod n\u00e1zvy Ozempic a Wegovy nebo tirzepatid zn\u00e1m\u00fd jako\u00a0Mounjaro<\/a>\u00a0\u010di Zepbound. P\u016fvodn\u011b byly ur\u010deny hlavn\u011b k l\u00e9\u010db\u011b cukrovky 2. typu, postupn\u011b se ale uk\u00e1zalo, \u017ee v\u00fdrazn\u011b pom\u00e1haj\u00ed i p\u0159i hubnut\u00ed. Funguj\u00ed mimo jin\u00e9 tak, \u017ee potla\u010duj\u00ed chu\u0165 k j\u00eddlu a zpomaluj\u00ed vyprazd\u0148ov\u00e1n\u00ed \u017ealudku.\u00a0<\/p>\n

Probl\u00e9my se zrakem a \u017ealudkem<\/p>\n

Pr\u00e1v\u011b zpomalen\u00ed tr\u00e1ven\u00ed ale podle n\u011bkter\u00fdch pacient\u016f vede k v\u00e1\u017en\u00fdm komplikac\u00edm. Ve Spojen\u00fdch st\u00e1tech nyn\u00ed p\u0159ib\u00fdv\u00e1 lid\u00ed, kte\u0159\u00ed tvrd\u00ed, \u017ee po u\u017e\u00edv\u00e1n\u00ed t\u011bchto p\u0159\u00edpravk\u016f utrp\u011bli trval\u00e9 zdravotn\u00ed n\u00e1sledky. Nej\u010dast\u011bji jde o dv\u011b oblasti \u2013 po\u0161kozen\u00ed zraku a probl\u00e9my se \u017ealudkem.\u00a0\u00a0<\/p>\n

\u010c\u00e1st \u017ealob se t\u00fdk\u00e1 onemocn\u011bn\u00ed zn\u00e1m\u00e9ho pod zkratkou NAION, kter\u00e9mu se n\u011bkdy p\u0159ezd\u00edv\u00e1 \u201eo\u010dn\u00ed mrtvice\u201c. Jde o po\u0161kozen\u00ed zrakov\u00e9ho nervu zp\u016fsoben\u00e9 nedostate\u010dn\u00fdm prokrven\u00edm, kter\u00e9 m\u016f\u017ee v\u00e9st k n\u00e1hl\u00e9 a nevratn\u00e9 ztr\u00e1t\u011b zraku na jednom oku. N\u011bkolik studi\u00ed v posledn\u00edch letech nazna\u010dilo, \u017ee se tento probl\u00e9m objevuje \u010dast\u011bji pr\u00e1v\u011b u pacient\u016f u\u017e\u00edvaj\u00edc\u00edch l\u00e9ky typu GLP-1.\u00a0<\/p>\n

Jedna z nejv\u011bt\u0161\u00edch\u00a0studi\u00ed<\/a>\u00a0sledovala t\u00e9m\u011b\u0159 600 tis\u00edc Ameri\u010dan\u016f s cukrovkou 2. typu po dobu t\u0159\u00ed let. V\u00fdzkumn\u00edci zjistili, \u017ee u lid\u00ed u\u017e\u00edvaj\u00edc\u00edch semaglutid nebo tirzepatid se NAION objevovala \u010dast\u011bji ne\u017e u pacient\u016f l\u00e9\u010den\u00fdch jin\u00fdmi antidiabetiky. Podle autora studie Ziyada Al-Alyho \u0161lo a\u017e o 35 procent vy\u0161\u0161\u00ed riziko.\u00a0<\/p>\n

Odborn\u00edci z\u00e1rove\u0148 zd\u016fraz\u0148uj\u00ed, \u017ee samotn\u00e9 onemocn\u011bn\u00ed je velmi vz\u00e1cn\u00e9. Evropsk\u00e1 l\u00e9kov\u00e1 agentura u\u017e nicm\u00e9n\u011b loni doporu\u010dila, aby v\u00fdrobci riziko mo\u017en\u00e9 ztr\u00e1ty zraku uv\u00e1d\u011bli mezi vedlej\u0161\u00edmi \u00fa\u010dinky t\u011bchto p\u0159\u00edpravk\u016f.\u00a0<\/p>\n

Komplikace u diabetik\u016f<\/p>\n

Dal\u0161\u00ed obavy vyvol\u00e1vaj\u00ed \u017ealude\u010dn\u00ed komplikace. N\u011bkter\u00e9\u00a0studie<\/a>\u00a0popsaly p\u0159\u00edpady gastropar\u00e9zy, tedy takzvan\u00e9 paral\u00fdzy \u017ealudku. P\u0159i n\u00ed \u017ealudek pracuje v\u00fdrazn\u011b pomaleji a potrava se neposouv\u00e1 spr\u00e1vn\u011b do st\u0159ev. Pacienti pak mohou trp\u011bt dlouhodobou nevolnost\u00ed, bolestmi b\u0159icha nebo opakovan\u00fdm zvracen\u00edm.\u00a0<\/p>\n

L\u00e9ka\u0159i upozor\u0148uj\u00ed, \u017ee ur\u010dit, zda za probl\u00e9my stoj\u00ed p\u0159\u00edmo l\u00e9ky, nebo samotn\u00e1 cukrovka, nen\u00ed jednoduch\u00e9. Pr\u00e1v\u011b diabetici toti\u017e maj\u00ed k podobn\u00fdm komplikac\u00edm vy\u0161\u0161\u00ed sklony i bez u\u017e\u00edv\u00e1n\u00ed t\u011bchto p\u0159\u00edpravk\u016f. P\u0159esto se podle americk\u00fdch m\u00e9di\u00ed u\u017e po\u010det spor\u016f vy\u0161plhal na ni\u017e\u0161\u00ed tis\u00edce a jednotliv\u00e9 p\u0159\u00edpady se za\u010d\u00ednaj\u00ed spojovat do hromadn\u00fdch \u017ealob.\u00a0<\/p>\n

Vedle v\u00e1\u017en\u00fdch zdravotn\u00edch komplikac\u00ed se st\u00e1le \u010dast\u011bji \u0159e\u0161\u00ed i dal\u0161\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky. Zn\u00e1m\u00fd je nap\u0159\u00edklad fenom\u00e9n takzvan\u00e9\u00a0\u201eozempicov\u00e9 tv\u00e1\u0159e\u201c<\/a>,\u00a0kdy rychl\u00fd \u00fabytek tuku zp\u016fsob\u00ed propadl\u00fd vzhled obli\u010deje a zv\u00fdrazn\u011bn\u00ed vr\u00e1sek.\u00a0<\/p>\n

Odborn\u00edci upozor\u0148uj\u00ed i na\u00a0dopady na dutinu \u00fastn\u00ed<\/a>.\u00a0Semaglutid m\u016f\u017ee sni\u017eovat produkci slin, co\u017e vede k suchu v \u00fastech, z\u00e1pachu z \u00fast nebo vy\u0161\u0161\u00edmu riziku vzniku zubn\u00edho kazu. Rizikov\u00e9 m\u016f\u017ee b\u00fdt i \u010dast\u00e9 zvracen\u00ed, kter\u00e9 po\u0161kozuje zubn\u00ed sklovinu p\u016fsoben\u00edm \u017ealude\u010dn\u00edch kyselin.\u00a0<\/p>\n

Navzdory nov\u00fdm zji\u0161t\u011bn\u00edm v\u011bt\u0161ina odborn\u00edk\u016f zd\u016fraz\u0148uje, \u017ee p\u0159\u00ednosy t\u011bchto l\u00e9k\u016f st\u00e1le v\u00fdrazn\u011b p\u0159eva\u017euj\u00ed nad riziky \u2013 zejm\u00e9na u pacient\u016f s obezitou nebo diabetem. Krom\u011b v\u00fdrazn\u00e9ho \u00fabytku hmotnosti toti\u017e mohou sni\u017eovat i riziko infarktu nebo dal\u0161\u00edch kardiovaskul\u00e1rn\u00edch komplikac\u00ed. Probl\u00e9m podle expert\u016f nast\u00e1v\u00e1 hlavn\u011b ve chv\u00edli, kdy je za\u010dnou u\u017e\u00edvat lid\u00e9 bez v\u00e1\u017en\u011bj\u0161\u00edch zdravotn\u00edch probl\u00e9m\u016f pouze kv\u016fli rychl\u00e9mu zhubnut\u00ed.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Popularita l\u00e9k\u016f na hubnut\u00ed, jako jsou Ozempic,\u00a0Wegovy nebo Mounjaro, d\u00e1l prudce roste. Jen ve Spojen\u00fdch st\u00e1tech je podle…\n","protected":false},"author":2,"featured_media":95403,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[7],"tags":[43,42,41,40,7605,5545,7604,4908,28594,113,28595,28782,555],"class_list":["post-95402","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cesko","tag-ceska-republika","tag-cesko","tag-czech-republic","tag-czechia","tag-diabetes","tag-hubnuti","tag-ozempic","tag-pacient","tag-tirzepatide","tag-usa","tag-vedlejsi-ucinek","tag-wegovy","tag-zaloba"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/116628235418754697","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/95402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=95402"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/95402\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/95403"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=95402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=95402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=95402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}